Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Completed · Phase 3 · Has a placebo group

Conditions studied: Hepatocellular Carcinoma

In brief

The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

Key facts

Study ID

NCT00908752

Run by

Bristol-Myers Squibb

People needed

734

Starts

2009-07-20

Expected to finish

2018-01-26

Last updated by the study team

2019-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with diagnosis of hepatocellular carcinoma
• Cirrhotic status of Child-Pugh Class A or B with a score of 7
• ECOG performance status of 0 or 1
• Adequate hematologic, hepatic, and renal function

You may not qualify if…

• Prior use of any systemic anticancer chemotherapy, immunotherapy, investigational or molecular targeted agents for HCC
• History of cardiac disease
• Active and untreated hepatitis B
• Inability to swallow tablets or untreated malabsorption syndrome
• History of human immunodeficiency virus (HIV) infection

Where it is running

• Sharp Clinical Oncology Research — San Diego, California, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Rhode Island Hospital — Providence, Rhode Island, United States
• The University Of Texas MD Anderson Cancer Center — Houston, Texas, United States
• University Of Virginia Health System — Charlottesville, Virginia, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Local Institution — Capital Federal, Buenos Aires, Argentina
• Local Institution — Buenos Aires, Argentina
• Local Institution — Parkville, Victoria, Australia
• Local Institution — Vancouver, British Columbia, Canada
• Local Institution — Montreal, Quebec, Canada
• Local Institution — Beijing, Beijing Municipality, China
• Local Institution — Guanzhou, Guangdong, China
• Local Institution — Nanning, Guangxi, China
• Local Institution — Harbin, Heilongjiang, China
• Local Institution — Changsha, Hunan, China
• Local Institution — Changzhou, Jiangsu, China
• Local Institution — Nanjing, Jiangsu, China
• Local Institution — Nanjing, Jiangsu, China
• Local Institution — Nanjing, Jiangsu, China
• Local Institution — Suzhou, Jiangsu, China
• Local Institution — Changchun, Jilin, China
• Local Institution — Xi'an, Shan3xi, China
• Local Institution — Shanghai, Shanghai Municipality, China
• Richard Finn, M.D. — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.